JP2010532381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532381A5 JP2010532381A5 JP2010515223A JP2010515223A JP2010532381A5 JP 2010532381 A5 JP2010532381 A5 JP 2010532381A5 JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010532381 A5 JP2010532381 A5 JP 2010532381A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- compound
- optionally substituted
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 86
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 67
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 44
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 44
- 229910052760 oxygen Inorganic materials 0.000 claims description 44
- 239000001301 oxygen Chemical group 0.000 claims description 44
- 229910052717 sulfur Chemical group 0.000 claims description 44
- 239000011593 sulfur Chemical group 0.000 claims description 44
- 125000005842 heteroatom Chemical group 0.000 claims description 42
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000002950 monocyclic group Chemical group 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- -1 oxadiadiolyl Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000008624 imidazolidinones Chemical class 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 2
- 125000005306 thianaphthenyl group Chemical group 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94731907P | 2007-06-29 | 2007-06-29 | |
| PCT/US2008/068789 WO2009006404A2 (en) | 2007-06-29 | 2008-06-30 | Heterocyclic compounds useful as raf kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010532381A JP2010532381A (ja) | 2010-10-07 |
| JP2010532381A5 true JP2010532381A5 (enExample) | 2012-07-26 |
Family
ID=40015666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515223A Pending JP2010532381A (ja) | 2007-06-29 | 2008-06-30 | Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7968536B2 (enExample) |
| EP (1) | EP2167497A2 (enExample) |
| JP (1) | JP2010532381A (enExample) |
| CN (1) | CN101743242A (enExample) |
| AU (1) | AU2008273017C1 (enExample) |
| CA (1) | CA2694284A1 (enExample) |
| NZ (1) | NZ582349A (enExample) |
| WO (1) | WO2009006404A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI444379B (zh) * | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| CA2737472A1 (en) * | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
| MX2011006997A (es) * | 2008-12-30 | 2011-10-21 | Sunesis Pharmaceuticals Inc | Compuestos de heteroarilo utiles como inhibidores de cinasa de factor recombinante activado (raf). |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| ES2549502T3 (es) | 2009-11-20 | 2015-10-28 | Sk Chemicals Co., Ltd. | Antagonistas de receptores de gonadoliberina, método de fabricación de los mismos, y composición farmacéutica que los contienen |
| WO2012142029A2 (en) | 2011-04-10 | 2012-10-18 | Florida A&M University | Serms for the treatment of estrogen receptor-mediated disorders |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2809659A1 (en) | 2012-02-03 | 2014-12-10 | Basf Se | Fungicidal pyrimidine compounds |
| EP2825533B1 (en) | 2012-03-13 | 2016-10-19 | Basf Se | Fungicidal pyrimidine compounds |
| CN102936251A (zh) * | 2012-11-05 | 2013-02-20 | 上海毕得医药科技有限公司 | 一种吡咯并[2,3-d]嘧啶衍生物的制备方法 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014144747A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CN105722833A (zh) | 2013-09-16 | 2016-06-29 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
| CN104761502A (zh) * | 2014-01-03 | 2015-07-08 | 中国药科大学 | 苯并咪唑衍生物、其制法及医药用途 |
| WO2015103901A1 (zh) * | 2014-01-08 | 2015-07-16 | 上海交通大学医学院 | 硬脂酰氨基酸盐及其制备方法和应用 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| KR20170032456A (ko) * | 2015-01-14 | 2017-03-22 | 가부시끼가이샤 도시바 | 비수 전해질 전지 및 전지 팩 |
| EP3185341B1 (fr) * | 2015-12-21 | 2019-09-11 | The Swatch Group Research and Development Ltd | Cathode de pile métal/air et procédés de fabrication d'une telle cathode |
| JP2019196307A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| CN106928152A (zh) * | 2017-03-03 | 2017-07-07 | 符爱清 | 一种尿嘧啶的制备方法 |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| EA039880B1 (ru) * | 2017-05-30 | 2022-03-23 | Дот Терапьютикс-1, Инк. | Способ получения оптически активного соединения |
| WO2019067623A1 (en) * | 2017-09-27 | 2019-04-04 | The Regents Of The University Of California | POWERFUL ANTIVIRAL COMPOUNDS CONTAINING PYRIDINE |
| US11725185B2 (en) | 2017-12-28 | 2023-08-15 | University Of Houston System | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| CN119823032A (zh) | 2018-02-01 | 2025-04-15 | 悉尼大学 | 抗癌化合物 |
| AU2020276695B2 (en) | 2019-05-13 | 2025-12-18 | Novartis Ag | New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer |
| US20230119479A1 (en) | 2019-12-10 | 2023-04-20 | Shionogi & Co., Ltd. | A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group |
| US20230159492A1 (en) * | 2020-03-02 | 2023-05-25 | Sironax Ltd. | Ferroptosis inhibitors - diarylamine para-acetamides |
| AU2021314955A1 (en) * | 2020-07-28 | 2023-03-30 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic Raf inhibitors and methods for use thereof |
| US12404242B2 (en) | 2021-12-17 | 2025-09-02 | Reglagene, Inc. | Compositions and methods for making and using small molecules in the treatment of cancer |
| CN121240859A (zh) | 2023-02-28 | 2025-12-30 | 瑞格拉基因有限公司 | 用于治疗健康状况的组合物和制备和使用小分子的方法 |
| CN117567388B (zh) * | 2023-11-14 | 2024-04-16 | 济南悟通生物科技有限公司 | 一种2-乙酰基-5-噻唑甲酸的合成方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5840917A (en) * | 1995-09-26 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Phosphorylamides, their preparation and use |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| CA2249607A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
| US5877182A (en) * | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| US6017925A (en) * | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
| AU6422798A (en) | 1997-03-25 | 1998-10-20 | Takeda Chemical Industries Ltd. | Stabilized urease inhibitor |
| US6214834B1 (en) * | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6632823B1 (en) * | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| JPH11209366A (ja) | 1998-01-23 | 1999-08-03 | Nissan Chem Ind Ltd | クロマン誘導体及び心不全治療薬 |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| EP1058549A4 (en) * | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| WO2000053602A1 (en) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| EP1171135A4 (en) * | 1999-03-10 | 2002-05-15 | Merck & Co Inc | 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE |
| WO2000058300A1 (en) | 1999-03-25 | 2000-10-05 | Nissan Chemical Industries, Ltd. | Chroman derivatives |
| US6127382A (en) * | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| JP2003514897A (ja) | 1999-11-24 | 2003-04-22 | シーオーアール セラピューティクス インコーポレイテッド | ベータ−アミノ酸系、アスパラギン酸系およびジアミノプロピオン酸系Ｘａ因子阻害剤 |
| GB0007245D0 (en) | 2000-03-24 | 2000-05-17 | Zeneca Ltd | Chemical compounds |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| EP1296678A2 (en) | 2000-06-21 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| EP1390034A4 (en) * | 2001-04-03 | 2005-07-13 | Merck & Co Inc | N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS |
| US7402585B2 (en) * | 2001-12-24 | 2008-07-22 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US20040048866A1 (en) * | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
| WO2003101444A1 (en) * | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| AU2003245669A1 (en) * | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| EP1554269A1 (en) * | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| EP1400244A1 (en) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| EP1547585A4 (en) | 2002-09-25 | 2008-05-14 | Santen Pharmaceutical Co Ltd | THERAPEUTIC AGENT AGAINST RHEUMA WITH A BENZAMIDE DERIVATIVE AS AN ACTIVE SUBSTANCE |
| JP2004161716A (ja) | 2002-11-15 | 2004-06-10 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| JP4847868B2 (ja) * | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| DE10328999B4 (de) | 2003-06-27 | 2006-08-31 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte |
| WO2005012304A2 (en) * | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| WO2005012307A1 (en) * | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| CN100412066C (zh) * | 2003-09-30 | 2008-08-20 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| KR101164541B1 (ko) | 2004-01-12 | 2012-07-10 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 선택적 키나제 저해제 |
| WO2005072733A1 (en) | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Dyarylurea compounds as chk-1 inhibitors |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| KR20070057792A (ko) * | 2004-07-16 | 2007-06-07 | 선에시스 파마슈티컬스 인코포레이티드 | 오로라 키나아제 저해물질로서 유용한 티에노피리미딘 |
| CA2584485C (en) | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| AU2005316668B2 (en) * | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006076442A2 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| TWI444379B (zh) * | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| MX2011006997A (es) | 2008-12-30 | 2011-10-21 | Sunesis Pharmaceuticals Inc | Compuestos de heteroarilo utiles como inhibidores de cinasa de factor recombinante activado (raf). |
-
2008
- 2008-06-30 CN CN200880022610A patent/CN101743242A/zh active Pending
- 2008-06-30 NZ NZ582349A patent/NZ582349A/en not_active IP Right Cessation
- 2008-06-30 US US12/164,905 patent/US7968536B2/en not_active Expired - Fee Related
- 2008-06-30 JP JP2010515223A patent/JP2010532381A/ja active Pending
- 2008-06-30 CA CA2694284A patent/CA2694284A1/en not_active Abandoned
- 2008-06-30 EP EP08781174A patent/EP2167497A2/en not_active Withdrawn
- 2008-06-30 AU AU2008273017A patent/AU2008273017C1/en not_active Expired - Fee Related
- 2008-06-30 WO PCT/US2008/068789 patent/WO2009006404A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532381A5 (enExample) | ||
| CN103384670B (zh) | 取代的咪唑并[1,2-b]哒嗪 | |
| KR101829940B1 (ko) | 프탈라지논 케톤 유도체, 이의 제조방법, 및 이의 약학적 용도 | |
| RU2589696C2 (ru) | КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА | |
| ES2968252T3 (es) | Compuesto 8,9-dihidroimidazol[1,2-a]pirimido[5,4-e]pirimidin-5(6H)-cetona | |
| CN114174292A (zh) | 作为atr激酶抑制剂的取代的2-吗啉代吡啶衍生物 | |
| CN113454080A (zh) | 化合物、药物组合物和制备化合物的方法以及其使用方法 | |
| ES2396177T3 (es) | Pirimidinas bicíclicas fusionadas | |
| EP3889152A1 (en) | Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof | |
| JP2010532380A5 (enExample) | ||
| WO2023066350A1 (zh) | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 | |
| EP3006445B1 (en) | Bisulfate of janus kinase (jak) inhibitor and preparation method therefor | |
| WO2023072297A1 (zh) | 含氮的四环化合物、其制备方法及其在医药上的应用 | |
| ES2558780T3 (es) | Imidazopiridazinas como inhibidores de la cinasa Akt | |
| EP3660018A1 (en) | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | |
| CN110167941B (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
| RS52313B (sr) | Jedinjenja za inhibiciju napredovanja mitoze | |
| CN111320624B (zh) | 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途 | |
| CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| JP2025525478A (ja) | Ｐｒｍｔ５・ｍｔａを阻害できる複素環化合物及びその用途 | |
| JP6736545B2 (ja) | 大環状ｒｉｐ２キナーゼ阻害剤 | |
| ES2589955T3 (es) | Pirazolopirimidinas sustituidas como inhibidores de la quinasa Akt | |
| EP2651949B1 (en) | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway | |
| WO2010053127A1 (ja) | α1GABAA受容体またはα5GABAA受容体の調整剤 | |
| EP4644382A1 (en) | Compound based on sulfur/oxygen substituted glutarimide-based isoindolinone skeleton and use thereof |